Literature DB >> 12084590

The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with diabetes mellitus.

Luis Gruberg1, Ron Waksman, Andrew E Ajani, Han-Soo Kim, R Lawrence White, Ellen E Pinnow, Lowell F Satler, Augusto D Pichard, Kenneth M Kent, Joseph Lindsay.   

Abstract

OBJECTIVES: The purpose of this study was to examine the effect of intracoronary radiation therapy (IRT) in diabetic patients with in-stent restenosis (ISR).
BACKGROUND: Diabetic patients are at an increased risk for restenosis, repeat revascularization procedures and late mortality after percutaneous coronary interventions and stenting. Intracoronary radiation therapy, utilizing both gamma and beta-emitters, has been shown to reduce the rate of ISR.
METHODS: The study group consisted of 749 consecutive patients with ISR who were treated with either IRT or placebo in randomized trials and registries at our center. Diabetic patients (252 radiation and 51 placebo) were compared with nondiabetic patients (371 radiation and 75 placebo).
RESULTS: In-hospital outcomes were similar between diabetic and nondiabetic patients treated with and without radiation. At six-month clinical and angiographic follow-up, there was a significant reduction in the binary restenosis (63.8% vs. 15.7%, p < 0.0001), target lesion revascularization (66.7% vs. 17.6%, p < 0.0001) and target vessel revascularization (TVR) (70.6% vs. 22.9%, p < 0.0001) rates in diabetic patients treated with radiation compared to placebo. Comparisons between the placebo arms detected a trend towards higher restenosis (63.8% vs. 48.4% p = 0.13) and TVR (70.6% vs. 56.0%, p = 0.14) in diabetic versus nondiabetic patients. In contrast, diabetic and nondiabetic patients treated with IRT experienced similar restenosis (15.6% vs. 10.7% p = 0.33) and TVR (22.9% vs. 28.2% p = 0.41) rates.
CONCLUSIONS: In diabetic patients with ISR, intracoronary radiation significantly reduced the recurrence of ISR compared to placebo. Additionally, similar rates of restenosis and revascularization procedures were achieved in irradiated diabetic and nondiabetic patients. In view of these results, IRT should be considered as a valuable therapeutic alternative in all diabetic patients with ISR.

Entities:  

Mesh:

Year:  2002        PMID: 12084590     DOI: 10.1016/s0735-1097(02)01891-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  Intracoronary brachytherapy for in-stent restenosis: will it remain a viable therapy?

Authors:  Seong-Wook Park; Myeong-Ki Hong; Seung Jun Oh; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-16       Impact factor: 9.236

Review 2.  Current understanding of coronary in-stent restenosis. Pathophysiology, clinical presentation, diagnostic work-up, and management.

Authors:  T M Schiele
Journal:  Z Kardiol       Date:  2005-11

3.  Characterizing the spectrum of in-stent restenosis: implications for contemporary treatment.

Authors:  Gordon E Pate; May Lee; Karin Humphries; Eric Cohen; Robert Lowe; Rebecca S Fox; Robert Teskey; Christopher E Buller
Journal:  Can J Cardiol       Date:  2006-12       Impact factor: 5.223

Review 4.  Diabetes and restenosis.

Authors:  Scott Wilson; Pasquale Mone; Urna Kansakar; Stanislovas S Jankauskas; Kwame Donkor; Ayobami Adebayo; Fahimeh Varzideh; Michael Eacobacci; Jessica Gambardella; Angela Lombardi; Gaetano Santulli
Journal:  Cardiovasc Diabetol       Date:  2022-02-14       Impact factor: 9.951

Review 5.  Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review.

Authors:  Chun-Wei Li; Kang Yu; Ng Shyh-Chang; Zongmin Jiang; Taoyan Liu; Shilin Ma; Lanfang Luo; Lu Guang; Kun Liang; Wenwu Ma; Hefan Miao; Wenhua Cao; Ruirui Liu; Ling-Juan Jiang; Song-Lin Yu; Chao Li; Hui-Jun Liu; Long-Yu Xu; Rong-Ji Liu; Xin-Yuan Zhang; Gao-Shan Liu
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-02-02       Impact factor: 12.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.